Business Description
Xilio Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US98422T1007
Total Employee Number:
76Description
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 22.65 | |||||
Equity-to-Asset | 0.44 | |||||
Debt-to-Equity | 0.09 | |||||
Debt-to-EBITDA | -0.16 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -2.78 | |||||
Beneish M-Score | 2.32 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 52.3 | |||||
3-Year EPS without NRI Growth Rate | 52.3 | |||||
3-Year FCF Growth Rate | 74.5 | |||||
3-Year Book Growth Rate | -47.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -42.61 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 45.67 | |||||
9-Day RSI | 44.18 | |||||
14-Day RSI | 46.56 | |||||
3-1 Month Momentum % | 8.42 | |||||
6-1 Month Momentum % | 2.35 | |||||
12-1 Month Momentum % | -6.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.59 | |||||
Quick Ratio | 3.59 | |||||
Cash Ratio | 3.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -32.2 | |||||
Shareholder Yield % | -61.01 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -78.98 | |||||
Net Margin % | -58.52 | |||||
EBITDA Margin % | -76.39 | |||||
FCF Margin % | -107.26 | |||||
OCF Margin % | -105.29 | |||||
ROE % | -133.2 | |||||
ROA % | -22.7 | |||||
ROIC % | -78.42 | |||||
3-Year ROIIC % | 162.6 | |||||
ROC (Joel Greenblatt) % | -526.03 | |||||
ROCE % | -48.79 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1.33 | |||||
PB Ratio | 0.69 | |||||
Price-to-Tangible-Book | 0.69 | |||||
EV-to-EBIT | 2.06 | |||||
EV-to-EBITDA | 2.13 | |||||
EV-to-Revenue | -1.62 | |||||
EV-to-FCF | 1.51 | |||||
| Price-to-Net-Current-Asset-Value | 0.79 | |||||
| Price-to-Net-Cash | 0.84 | |||||
Earnings Yield (Greenblatt) % | 48.54 | |||||
FCF Yield % | -100.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:XLO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xilio Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 53.484 | ||
| EPS (TTM) ($) | -3.55 | ||
| Beta | -1.081 | ||
| 3-Year Sharpe Ratio | -0.16 | ||
| 3-Year Sortino Ratio | -0.24 | ||
| Volatility % | 39.17 | ||
| 14-Day RSI | 46.56 | ||
| 14-Day ATR ($) | 0.432873 | ||
| 20-Day SMA ($) | 9.03 | ||
| 12-1 Month Momentum % | -6.74 | ||
| 52-Week Range ($) | 6.4652 - 12.7386 | ||
| Shares Outstanding (Mil) | 6.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xilio Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xilio Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 110 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 19 days | ||
| General meeting for 2026 | 2026-06-10 11:00 | 7.90 (+3.67%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 7.73 (-2.28%) | ||
| Annual report for 2025 | 2026-03-23 | 7.86 (+8.41%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-23 | 7.86 (+8.41%) | ||
| 0.0714286:1 Stock Split | 2026-03-16 | 7.14 (-0.23%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-09 15:00 | 7.42 (-1.87%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 10.83 (+0.16%) | ||
| Vilastobart in MSS CRC Patients with High Plasma TMB | 2025-11-10 16:30 | 11.30 (-5.06%) |
Show
Entries
Xilio Therapeutics Inc Frequently Asked Questions
What is Xilio Therapeutics Inc(XLO)'s stock price today?
The current price of XLO is $8.64. The 52 week high of XLO is $12.74 and 52 week low is $6.47.
When is next earnings date of Xilio Therapeutics Inc(XLO)?
The next earnings date of Xilio Therapeutics Inc(XLO) is 2026-08-14 Est..
Does Xilio Therapeutics Inc(XLO) pay dividends? If so, how much?
Xilio Therapeutics Inc(XLO) does not pay dividend.
Guru Commentaries on NAS:XLO
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Xilio Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers